25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Cara Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Cara Therapeutics Inc together

I guess you are interested in Cara Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cara Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Cara Therapeutics Inc

I send you an email if I find something interesting about Cara Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Cara Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Cara Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€0.01
Expected worth in 1 year
€-1.49
How sure are you?
15.4%

+ What do you gain per year?

Total Gains per Share
€-1.50
Return On Investment
-36.1%

For what price can you sell your share?

Current Price per Share
€4.16
Expected price per share
€4.1616 - €4.1616
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Cara Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
€4.16
Intrinsic Value Per Share
€-9.18 - €-10.45
Total Value Per Share
€-9.17 - €-10.44

2.2. Growth of Cara Therapeutics Inc (5 min.)




Is Cara Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$707k$122.4m-$97.6m-393.9%

How much money is Cara Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$23.8m-$29.1m$5.2m22.0%
Net Profit Margin-1,255.5%-598.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Cara Therapeutics Inc (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Cara Therapeutics Inc?

Welcome investor! Cara Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Cara Therapeutics Inc.

First you should know what it really means to hold a share of Cara Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Cara Therapeutics Inc is €4.1616. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cara Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cara Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.01. Based on the TTM, the Book Value Change Per Share is €-0.38 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.45 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cara Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.23-5.5%-0.44-10.5%-0.54-12.9%-0.43-10.3%-0.43-10.3%
Usd Book Value Change Per Share-0.20-4.8%-0.39-9.4%-0.47-11.2%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.20-4.8%-0.39-9.4%-0.47-11.2%0.000.0%0.000.0%
Usd Price Per Share0.27-0.53-4.85-5.85-5.85-
Price to Earnings Ratio-0.30--0.29--2.23--17.31--17.31-
Price-to-Total Gains Ratio-1.38--1.32--10.33--250.76--250.76-
Price to Book Ratio21.23-6.20-1.94-3.58-3.58-
Price-to-Total Gains Ratio-1.38--1.32--10.33--250.76--250.76-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.32431856
Number of shares231
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.390.00
Usd Total Gains Per Share-0.390.00
Gains per Quarter (231 shares)-90.050.23
Gains per Year (231 shares)-360.220.92
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-360-37001-9
20-720-73002-8
30-1081-109003-7
40-1441-145004-6
50-1801-181005-5
60-2161-217005-4
70-2522-253006-3
80-2882-289007-2
90-3242-325008-1
100-3602-3610090

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.013.00.00.0%0.013.00.00.0%0.013.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%2.011.00.015.4%2.011.00.015.4%2.011.00.015.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.013.00.0%0.00.013.00.0%0.00.013.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%2.011.00.015.4%2.011.00.015.4%2.011.00.015.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Cara Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.191-0.375+96%-0.449+135%0.001-20126%0.001-20126%
Book Value Per Share--0.0120.437-97%2.182-99%2.245-99%2.245-99%
Current Ratio--4.7734.822-1%6.263-24%6.805-30%6.805-30%
Debt To Asset Ratio--0.9860.760+30%0.171+476%0.323+205%0.323+205%
Debt To Equity Ratio--71.60120.020+258%0.213+33584%6.266+1043%6.266+1043%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value---34274345.762-30143958.118-12%228916029.535-115%266096649.503-113%266096649.503-113%
Eps---0.219-0.420+92%-0.518+137%-0.413+88%-0.413+88%
Ev To Ebitda Ratio--infinfnan%infnan%nannan%nannan%
Ev To Sales Ratio---3.483-4.771+37%14.541-124%20.560-117%20.560-117%
Free Cash Flow Per Share---0.245-0.340+39%-0.439+79%-0.339+38%-0.339+38%
Free Cash Flow To Equity Per Share---0.258-0.188-27%-0.431+67%-0.226-12%-0.226-12%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---10.453--------
Intrinsic Value_10Y_min---9.178--------
Intrinsic Value_1Y_max---1.331--------
Intrinsic Value_1Y_min---1.307--------
Intrinsic Value_3Y_max---3.783--------
Intrinsic Value_3Y_min---3.616--------
Intrinsic Value_5Y_max---5.974--------
Intrinsic Value_5Y_min---5.564--------
Market Cap--14444267.03827738146.282-48%251842562.935-94%298958019.595-95%298958019.595-95%
Net Profit Margin---4.881-12.555+157%-5.983+23%-9.460+94%-9.460+94%
Operating Margin----0%-0%-0%-0%
Operating Ratio--3.06611.261-73%7.572-60%10.012-69%10.012-69%
Pb Ratio335.402+94%21.2296.198+242%1.935+997%3.580+493%3.580+493%
Pe Ratio-4.752-1480%-0.301-0.293-3%-2.232+642%-17.306+5654%-17.306+5654%
Price Per Share4.162+94%0.2630.508-48%4.670-94%5.630-95%5.630-95%
Price To Free Cash Flow Ratio-4.239-1480%-0.268-0.362+35%-2.668+894%-13.597+4968%-13.597+4968%
Price To Total Gains Ratio-21.773-1480%-1.378-1.315-5%-10.334+650%-250.761+18096%-250.761+18096%
Quick Ratio--0.5391.185-55%2.664-80%3.735-86%3.735-86%
Return On Assets---0.243-0.279+15%-0.204-16%-0.179-26%-0.179-26%
Return On Equity---17.646-5.242-70%-0.251-99%-1.723-90%-1.723-90%
Total Gains Per Share---0.191-0.375+96%-0.449+135%0.001-20126%0.001-20126%
Usd Book Value--707021.09724798989.980-97%122491405.034-99%124404789.051-99%124404789.051-99%
Usd Book Value Change Per Share---0.199-0.390+96%-0.467+135%0.001-20126%0.001-20126%
Usd Book Value Per Share--0.0130.454-97%2.267-99%2.333-99%2.333-99%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value---35614472.682-31322586.881-12%237866646.290-115%276501028.499-113%276501028.499-113%
Usd Eps---0.228-0.437+92%-0.539+137%-0.429+88%-0.429+88%
Usd Free Cash Flow---13984417.283-19336076.971+38%-24635985.116+76%-18965642.841+36%-18965642.841+36%
Usd Free Cash Flow Per Share---0.255-0.354+39%-0.456+79%-0.352+38%-0.352+38%
Usd Free Cash Flow To Equity Per Share---0.268-0.195-27%-0.448+67%-0.235-12%-0.235-12%
Usd Market Cap--15009037.87928822707.801-48%261689607.146-94%310647278.161-95%310647278.161-95%
Usd Price Per Share4.324+94%0.2740.527-48%4.852-94%5.850-95%5.850-95%
Usd Profit---12476372.284-23881962.617+91%-29129619.202+133%-23198384.527+86%-23198384.527+86%
Usd Revenue--2556076.2712171564.798+18%5306408.339-52%6893282.612-63%6893282.612-63%
Usd Total Gains Per Share---0.199-0.390+96%-0.467+135%0.001-20126%0.001-20126%
 EOD+3 -3MRQTTM+17 -18YOY+16 -195Y+10 -2510Y+10 -25

3.3 Fundamental Score

Let's check the fundamental score of Cara Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.752
Price to Book Ratio (EOD)Between0-1335.402
Net Profit Margin (MRQ)Greater than0-4.881
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.539
Current Ratio (MRQ)Greater than14.773
Debt to Asset Ratio (MRQ)Less than10.986
Debt to Equity Ratio (MRQ)Less than171.601
Return on Equity (MRQ)Greater than0.15-17.646
Return on Assets (MRQ)Greater than0.05-0.243
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of Cara Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.146
Ma 20Greater thanMa 504.162
Ma 50Greater thanMa 1003.650
Ma 100Greater thanMa 2003.348
OpenGreater thanClose4.162
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Cara Therapeutics Inc

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Cara Therapeutics Inc earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Cara Therapeutics Inc to the  industry mean.
  • A Net Profit Margin of -488.1% means that €-4.88 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cara Therapeutics Inc:

  • The MRQ is -488.1%. The company is making a huge loss. -2
  • The TTM is -1,255.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-488.1%TTM-1,255.5%+767.4%
TTM-1,255.5%YOY-598.3%-657.3%
TTM-1,255.5%5Y-946.0%-309.5%
5Y-946.0%10Y-946.0%0.0%
4.3.1.2. Return on Assets

Shows how efficient Cara Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cara Therapeutics Inc to the  industry mean.
  • -24.3% Return on Assets means that Cara Therapeutics Inc generated €-0.24 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cara Therapeutics Inc:

  • The MRQ is -24.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -27.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-24.3%TTM-27.9%+3.6%
TTM-27.9%YOY-20.4%-7.5%
TTM-27.9%5Y-17.9%-10.0%
5Y-17.9%10Y-17.9%0.0%
4.3.1.3. Return on Equity

Shows how efficient Cara Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cara Therapeutics Inc to the  industry mean.
  • -1,764.6% Return on Equity means Cara Therapeutics Inc generated €-17.65 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cara Therapeutics Inc:

  • The MRQ is -1,764.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -524.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1,764.6%TTM-524.2%-1,240.4%
TTM-524.2%YOY-25.1%-499.2%
TTM-524.2%5Y-172.3%-351.9%
5Y-172.3%10Y-172.3%0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Cara Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Cara Therapeutics Inc is operating .

  • Measures how much profit Cara Therapeutics Inc makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cara Therapeutics Inc to the  industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cara Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
4.3.2.2. Operating Ratio

Measures how efficient Cara Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 3.07 means that the operating costs are €3.07 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Cara Therapeutics Inc:

  • The MRQ is 3.066. The company is inefficient in keeping operating costs low. -1
  • The TTM is 11.261. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.066TTM11.261-8.195
TTM11.261YOY7.572+3.689
TTM11.2615Y10.012+1.248
5Y10.01210Y10.0120.000
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Cara Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Cara Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 4.77 means the company has €4.77 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Cara Therapeutics Inc:

  • The MRQ is 4.773. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.822. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.773TTM4.822-0.049
TTM4.822YOY6.263-1.441
TTM4.8225Y6.805-1.983
5Y6.80510Y6.8050.000
4.4.3.2. Quick Ratio

Measures if Cara Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cara Therapeutics Inc to the  industry mean.
  • A Quick Ratio of 0.54 means the company can pay off €0.54 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cara Therapeutics Inc:

  • The MRQ is 0.539. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.185. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ0.539TTM1.185-0.646
TTM1.185YOY2.664-1.479
TTM1.1855Y3.735-2.550
5Y3.73510Y3.7350.000
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Cara Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Cara Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cara Therapeutics Inc to industry mean.
  • A Debt to Asset Ratio of 0.99 means that Cara Therapeutics Inc assets are financed with 98.6% credit (debt) and the remaining percentage (100% - 98.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cara Therapeutics Inc:

  • The MRQ is 0.986. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.760. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.986TTM0.760+0.226
TTM0.760YOY0.171+0.589
TTM0.7605Y0.323+0.437
5Y0.32310Y0.3230.000
4.5.4.2. Debt to Equity Ratio

Measures if Cara Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cara Therapeutics Inc to the  industry mean.
  • A Debt to Equity ratio of 7,160.1% means that company has €71.60 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cara Therapeutics Inc:

  • The MRQ is 71.601. The company is unable to pay all its debts with equity. -1
  • The TTM is 20.020. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ71.601TTM20.020+51.581
TTM20.020YOY0.213+19.807
TTM20.0205Y6.266+13.754
5Y6.26610Y6.2660.000
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Cara Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Cara Therapeutics Inc to the  industry mean.
  • A PE ratio of -0.30 means the investor is paying €-0.30 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cara Therapeutics Inc:

  • The EOD is -4.752. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.301. Based on the earnings, the company is expensive. -2
  • The TTM is -0.293. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.752MRQ-0.301-4.451
MRQ-0.301TTM-0.293-0.008
TTM-0.293YOY-2.232+1.939
TTM-0.2935Y-17.306+17.013
5Y-17.30610Y-17.3060.000
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cara Therapeutics Inc:

  • The EOD is -4.239. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.268. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.362. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.239MRQ-0.268-3.971
MRQ-0.268TTM-0.362+0.094
TTM-0.362YOY-2.668+2.305
TTM-0.3625Y-13.597+13.235
5Y-13.59710Y-13.5970.000
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Cara Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 21.23 means the investor is paying €21.23 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Cara Therapeutics Inc:

  • The EOD is 335.402. Based on the equity, the company is expensive. -2
  • The MRQ is 21.229. Based on the equity, the company is expensive. -2
  • The TTM is 6.198. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD335.402MRQ21.229+314.173
MRQ21.229TTM6.198+15.030
TTM6.198YOY1.935+4.263
TTM6.1985Y3.580+2.618
5Y3.58010Y3.5800.000
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets51,329
Total Liabilities50,622
Total Stockholder Equity707
 As reported
Total Liabilities 50,622
Total Stockholder Equity+ 707
Total Assets = 51,329

Assets

Total Assets51,329
Total Current Assets47,912
Long-term Assets3,417
Total Current Assets
Cash And Cash Equivalents 37,061
Short-term Investments 4,975
Net Receivables 435
Inventory 625
Total Current Assets  (as reported)47,912
Total Current Assets  (calculated)43,096
+/- 4,816
Long-term Assets
Property Plant Equipment 3,417
Long-term Assets  (as reported)3,417
Long-term Assets  (calculated)3,417
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities10,039
Long-term Liabilities40,583
Total Stockholder Equity707
Total Current Liabilities
Accounts payable 2,541
Total Current Liabilities  (as reported)10,039
Total Current Liabilities  (calculated)2,541
+/- 7,498
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt3,417
Long-term Liabilities Other 40,583
Long-term Liabilities  (as reported)40,583
Long-term Liabilities  (calculated)44,000
+/- 3,417
Total Stockholder Equity
Total Stockholder Equity (as reported)707
Total Stockholder Equity (calculated)0
+/- 707
Other
Capital Stock54
Common Stock Shares Outstanding 54,838
Net Invested Capital 707
Net Working Capital 37,873
Property Plant and Equipment Gross 3,417



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
> Total Assets 
225,092
247,056
223,866
226,572
213,509
182,237
153,276
134,389
115,338
125,844
90,099
72,495
51,329
51,32972,49590,099125,844115,338134,389153,276182,237213,509226,572223,866247,056225,092
   > Total Current Assets 
171,499
173,290
151,762
176,166
186,780
168,910
142,659
124,736
100,603
116,158
81,225
63,859
47,912
47,91263,85981,225116,158100,603124,736142,659168,910186,780176,166151,762173,290171,499
       Cash And Cash Equivalents 
22,991
13,453
21,362
46,718
42,806
63,741
47,391
58,249
62,875
51,775
46,996
49,239
37,061
37,06149,23946,99651,77562,87558,24947,39163,74142,80646,71821,36213,45322,991
       Short-term Investments 
121,203
153,582
119,749
110,794
112,806
81,658
66,892
36,442
15,666
48,983
22,777
7,379
4,975
4,9757,37922,77748,98315,66636,44266,89281,658112,806110,794119,749153,582121,203
       Net Receivables 
0
0
2,496
8,003
9,623
3,260
6,066
10,124
3,351
2,765
1,718
359
435
4353591,7182,7653,35110,1246,0663,2609,6238,0032,49600
   > Long-term Assets 
53,593
73,766
72,104
50,406
26,729
13,327
10,617
9,653
14,735
9,686
8,874
8,636
3,417
3,4178,6368,8749,68614,7359,65310,61713,32726,72950,40672,10473,76653,593
       Property Plant Equipment 
0
0
0
0
2,405
1,977
1,543
1,100
8,488
8,186
7,374
7,136
3,417
3,4177,1367,3748,1868,4881,1001,5431,9772,4050000
       Long Term Investments 
49,221
69,754
68,456
47,171
23,916
11,350
9,074
7,053
4,747
0
0
0
0
00004,7477,0539,07411,35023,91647,17168,45669,75449,221
       Long-term Assets Other 
408
408
408
408
408
0
0
1,500
1,500
1,500
1,500
1,500
0
01,5001,5001,5001,5001,50000408408408408408
> Total Liabilities 
17,901
19,534
19,751
22,150
28,689
23,458
16,678
25,457
29,696
68,759
60,296
60,897
50,622
50,62260,89760,29668,75929,69625,45716,67823,45828,68922,15019,75119,53417,901
   > Total Current Liabilities 
15,528
17,616
18,296
21,167
28,192
23,458
16,678
25,457
22,881
25,592
15,095
13,901
10,039
10,03913,90115,09525,59222,88125,45716,67823,45828,19221,16718,29617,61615,528
       Accounts payable 
5,369
5,625
5,594
9,740
15,218
9,604
4,424
12,122
7,978
11,583
4,978
6,755
2,541
2,5416,7554,97811,5837,97812,1224,4249,60415,2189,7405,5945,6255,369
   > Long-term Liabilities 
2,373
1,918
1,455
983
497
0
0
0
6,815
43,167
45,201
46,996
40,583
40,58346,99645,20143,1676,8150004979831,4551,9182,373
       Capital Lease Obligations Min Short Term Debt
4,089
3,673
3,250
2,818
2,373
1,918
1,456
982
7,312
6,088
7,045
7,488
3,417
3,4177,4887,0456,0887,3129821,4561,9182,3732,8183,2503,6734,089
> Total Stockholder Equity
207,191
227,522
204,115
204,422
184,820
158,779
136,598
108,932
85,642
57,085
29,803
11,598
707
70711,59829,80357,08585,642108,932136,598158,779184,820204,422204,115227,522207,191
   Common Stock0000000000000
   Retained Earnings Total Equity0000000000000
   Accumulated Other Comprehensive Income 0000000000000
   Capital Surplus 0000000000000
   Treasury Stock0000000000000
   Other Stockholders Equity 0000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue20,968
Cost of Revenue-6,174
Gross Profit14,79414,794
 
Operating Income (+$)
Gross Profit14,794
Operating Expense-142,463
Operating Income-121,495-127,669
 
Operating Expense (+$)
Research Development108,510
Selling General Administrative27,649
Selling And Marketing Expenses-
Operating Expense142,463136,159
 
Net Interest Income (+$)
Interest Income-
Interest Expense-604
Other Finance Cost-0
Net Interest Income-604
 
Pretax Income (+$)
Operating Income-121,495
Net Interest Income-604
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-118,513-125,081
EBIT - interestExpense = -604
-118,513
-117,909
Interest Expense604
Earnings Before Interest and Taxes (EBIT)--117,909
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-118,513
Tax Provision--
Net Income From Continuing Ops-118,513-118,513
Net Income-118,513
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net3,586604
 

Technical Analysis of Cara Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cara Therapeutics Inc. The general trend of Cara Therapeutics Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cara Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cara Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 4.1616 < 4.1616 < 4.1616.

The bearish price targets are: 4.1616 > 4.1616 > 4.1616.

Tweet this
Cara Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cara Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cara Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cara Therapeutics Inc. The current macd is 0.14127041.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cara Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Cara Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Cara Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Cara Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartCara Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cara Therapeutics Inc. The current adx is 28.15.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cara Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Cara Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cara Therapeutics Inc. The current sar is 5.257632.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Cara Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cara Therapeutics Inc. The current rsi is 60.15. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
Cara Therapeutics Inc Daily Relative Strength Index (RSI) ChartCara Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cara Therapeutics Inc. The current phase is Oversold in neutral market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cara Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Cara Therapeutics Inc Daily Stochastic Oscillator ChartCara Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cara Therapeutics Inc. The current cci is 66.67.

Cara Therapeutics Inc Daily Commodity Channel Index (CCI) ChartCara Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cara Therapeutics Inc. The current cmo is 20.50.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Cara Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartCara Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cara Therapeutics Inc. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Cara Therapeutics Inc Daily Williams %R ChartCara Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cara Therapeutics Inc.

Cara Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cara Therapeutics Inc. The current atr is 0.07014177.

Cara Therapeutics Inc Daily Average True Range (ATR) ChartCara Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cara Therapeutics Inc. The current obv is 6,422.

Cara Therapeutics Inc Daily On-Balance Volume (OBV) ChartCara Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cara Therapeutics Inc. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Cara Therapeutics Inc Daily Money Flow Index (MFI) ChartCara Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cara Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-09-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-10-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-11-28MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-12-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-23MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-01-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-01-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside

6.3. Candlestick Patterns

Cara Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cara Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.146
Ma 20Greater thanMa 504.162
Ma 50Greater thanMa 1003.650
Ma 100Greater thanMa 2003.348
OpenGreater thanClose4.162
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Cara Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Cara Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cara Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cara Therapeutics Inc

I send you an email if I find something interesting about Cara Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cara Therapeutics Inc.

Receive notifications about Cara Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.